Accelerate Diagnostics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
Accelerate Diagnostics Stock Forecast and Price Target
According to experts, who recently provided their 2024 price targets for Accelerate Diagnostics, the average price target is $0.50, with a high estimate of $0.56 and a low estimate of $0.45. That is a potential downside of approximately -46.24% from the last closing price of $0.93 on April, 2024. Although you may not be interested in AXDX stock, you should still be aware of its competitors.
-46.24% Downside
Accelerate Diagnostics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Accelerate Diagnostics's Price has grown by 100.00%, from $0.00 to $0.00. For the next year, analysts are expecting Fair Value to reach $1.00 – an increase of 100.00%. Over the next seven years, experts predict that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$573.60 | Buy/Sell | $591.94 | 7.22% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF221.00 | Buy/Sell | CHF307.83 | 23.30% |
| DHR Stock Forecast | Danaher | Outperform |
10
|
$246.58 | Buy/Sell | $260.33 | 9.50% |
| SIE Stock Forecast | Siemens | Outperform |
10
|
177.62€ | Buy/Sell | 178.14€ | 10.07% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$231.55 | Buy/Sell | $284.47 | 19.84% |
Accelerate Diagnostics Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Accelerate Diagnostics's Revenue has grown by 14.15%, from $11.17M to $12.75M. For the next year, analysts are expecting Revenue to reach $18.96M – an increase of 48.71%. Over the next seven years, experts predict that Revenue will grow by 55.34%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SHL Stock Forecast | Siemens Healthineers | Buy |
8
|
52.94€ | Buy/Sell | 56.34€ | 13.34% |
| ILMN Stock Forecast | Illumina | Outperform |
16
|
$122.28 | Buy/Sell | $159.28 | 22.67% |
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$75.98 | Buy/Sell | $81.06 | 10.56% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$134.26 | Buy/Sell | $141.17 | 8.00% |
| BIM Stock Forecast | bioMérieux | Outperform |
18
|
101.50€ | Buy/Sell | 105.55€ | 12.32% |
| QGEN Stock Forecast | QIAGEN N.V. | Outperform |
15
|
$41.65 | Buy/Sell | $0.00 | 20.05% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| QDEL Stock Forecast | Quidel Corp | Hold |
16
|
$39.64 | Buy/Sell | $121.00 | 34.21% |
| NEO Stock Forecast | NeoGenomics | Outperform |
8
|
$14.14 | Buy/Sell | $20.09 | 41.44% |
| VCYT Stock Forecast | Veracyte | Outperform |
11
|
$19.31 | Buy/Sell | $32.17 | 68.31% |
Accelerate Diagnostics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Accelerate Diagnostics's EBITDA has fallen from $-60.30M to $-59.81M – a 0.81% decrease. For next year, analysts predict EBITDA of $-63.41M, which would mean an increase of 6.02%. Over the next eight years, experts predict that Accelerate Diagnostics's EBITDA will grow at a rate of 6.35%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A096530 Stock Forecast | Seegene | Outperform |
18
|
₩21.90k | Buy/Sell | ₩25.00k | 14.16% |
| CRDF Stock Forecast | Cardiff Oncology | Buy |
10
|
$4.07 | Buy/Sell | $8.37 | 113.27% |
| BCART Stock Forecast | Biocartis Group NV | Outperform |
7
|
0.29€ | Buy/Sell | 1.10€ | -100.00% |
Accelerate Diagnostics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Accelerate Diagnostics's EBIT has decreased from $-63.30M to $-62.81M – a 0.77% drop. In the following year, 1 experts forecast that Accelerate Diagnostics's EBIT will decrease by 53.34%, to $-29.31M. In 2030, professionals predict that Accelerate Diagnostics's EBIT will decrease by 30.08%, to $-43.92M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TTOO Stock Forecast | T2 Biosystems | - |
6
|
$2.84 | Buy/Sell | $8.68 | -100.00% |
| OPGN Stock Forecast | OpGen |
2
|
$0.51 | Buy/Sell | $3.00 | -100.00% | |
| IDXG Stock Forecast | Interpace Biosciences | - |
0
|
$1.06 | Buy/Sell | $11.00 | -100.00% |
Accelerate Diagnostics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Accelerate Diagnostics's EPS has grown by 100.00%, from $-14.00 to $0.00. For the next year, analysts are expecting EPS to reach $-2.09 – an increase of 100.00%. Over the next seven years, experts predict that EPS will grow by 100.00%.
Site Navigation
.jpg)